Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Health insurers utilising analytics for profitable growth
How can you boost ROI by embedding analytics into new product design, new business strategies and pricing approaches? Rising disease burdens and aging
Pensions dashboard is coming what should corporates expect
The pensions dashboard is expected to be available to the public later this year. This will be a major moment for UK retirement saving, changing how e
Buyin to buyout navigating the post transaction bottleneck
Our 2026 survey results provide a detailed view of how all 11 active insurers are progressing schemes from initial buy-in to full buyout – the point a

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.